A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores
Standard
A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. / Leyh-Bannurah, Sami-Ramzi; Trudel, Dominique; Latour, Mathieu; Zaffuto, Emanuele; Grosset, Andree-Anne; Tam, Christine; Ouellet, Veronique; Graefen, Markus; Budäus, Lars; Aprikian, Armen G; Lacombe, Louis; Fleshner, Neil E; Gleave, Martin E; Mes-Masson, Anne-Marie; Saad, Fred; Karakiewicz, Pierre I.
In: PATHOL ONCOL RES, Vol. 25, No. 3, 07.2019, p. 979-986.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores
AU - Leyh-Bannurah, Sami-Ramzi
AU - Trudel, Dominique
AU - Latour, Mathieu
AU - Zaffuto, Emanuele
AU - Grosset, Andree-Anne
AU - Tam, Christine
AU - Ouellet, Veronique
AU - Graefen, Markus
AU - Budäus, Lars
AU - Aprikian, Armen G
AU - Lacombe, Louis
AU - Fleshner, Neil E
AU - Gleave, Martin E
AU - Mes-Masson, Anne-Marie
AU - Saad, Fred
AU - Karakiewicz, Pierre I
PY - 2019/7
Y1 - 2019/7
N2 - To test the agreement between high-grade PCa at RP and TMA, and the ability of TMA to predict BCR. Validation of concordance between tissue microarray (TMA) and radical prostatectomy (RP) high-grade prostate cancer (PCa) is crucial because latter determines the treated natural history of PCa. We hypothesized that TMA Gleason score is in agreement with RP pathology and capable of accurately predicting biochemical recurrence (BCR). Data were provided from a multi-institutional Canadian sample of 1333 TMA and RP specimens with complete clinicopathological data. First, rate of agreement between TMA and high-grade Gleason at RP or biopsy and RP was tested. Second, ability of RP, TMA and biopsy to predict BCR was compared. Multivariable (MVA) Cox regression models were fitted and BCR rates were illustrated with Kaplan-Meier plots. Agreement between RP and TMA and between RP and biopsy was 72.6% (95% CI:69.7-75.5) and 60.4% (95% CI:57.2-63.6), respectively. In MVA predicting BCR, the accuracy for RP, TMA and biopsy was 0.73, 0.72 and 0.68, respectively. TMA added discriminatory ability among exclusively low-grade Gleason RP patients (p = 0.02), but did not improve BCR discrimination in exclusive high-grade PCa RP patients (p = 0.8). TMA Gleason grade accurately reflects presence of high-grade Gleason in RP specimen, accurately predicts BCR rates after RP and improves prediction of BCR in low-grade Gleason patients at RP.
AB - To test the agreement between high-grade PCa at RP and TMA, and the ability of TMA to predict BCR. Validation of concordance between tissue microarray (TMA) and radical prostatectomy (RP) high-grade prostate cancer (PCa) is crucial because latter determines the treated natural history of PCa. We hypothesized that TMA Gleason score is in agreement with RP pathology and capable of accurately predicting biochemical recurrence (BCR). Data were provided from a multi-institutional Canadian sample of 1333 TMA and RP specimens with complete clinicopathological data. First, rate of agreement between TMA and high-grade Gleason at RP or biopsy and RP was tested. Second, ability of RP, TMA and biopsy to predict BCR was compared. Multivariable (MVA) Cox regression models were fitted and BCR rates were illustrated with Kaplan-Meier plots. Agreement between RP and TMA and between RP and biopsy was 72.6% (95% CI:69.7-75.5) and 60.4% (95% CI:57.2-63.6), respectively. In MVA predicting BCR, the accuracy for RP, TMA and biopsy was 0.73, 0.72 and 0.68, respectively. TMA added discriminatory ability among exclusively low-grade Gleason RP patients (p = 0.02), but did not improve BCR discrimination in exclusive high-grade PCa RP patients (p = 0.8). TMA Gleason grade accurately reflects presence of high-grade Gleason in RP specimen, accurately predicts BCR rates after RP and improves prediction of BCR in low-grade Gleason patients at RP.
KW - Journal Article
U2 - 10.1007/s12253-018-0408-6
DO - 10.1007/s12253-018-0408-6
M3 - SCORING: Journal article
C2 - 29623528
VL - 25
SP - 979
EP - 986
JO - PATHOL ONCOL RES
JF - PATHOL ONCOL RES
SN - 1219-4956
IS - 3
ER -